Business Description
LAVA Therapeutics NV
Compare
Compare
Traded in other countries / regions
4PKB.GermanyLVTX.USA IPO Date
2021-03-25Description
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.01 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0.1 | |||||
| Beneish M-Score | 6.97 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.15 | |||||
| 9-Day RSI | 22.93 | |||||
| 14-Day RSI | 25.82 | |||||
| 6-1 Month Momentum % | -10.7 | |||||
| 12-1 Month Momentum % | -56.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.26 | |||||
| Quick Ratio | 8.26 | |||||
| Cash Ratio | 5.19 | |||||
| Days Sales Outstanding | 223.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -191.32 | |||||
| Net Margin % | -164.45 | |||||
| ROE % | -26.47 | |||||
| ROA % | -20.94 | |||||
| ROIC % | -186.72 | |||||
| ROC (Joel Greenblatt) % | -338.4 | |||||
| ROCE % | -24.5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.4 | |||||
| PB Ratio | 0.45 | |||||
| Price-to-Tangible-Book | 0.45 | |||||
| EV-to-EBIT | 1.55 | |||||
| EV-to-EBITDA | 1.58 | |||||
| EV-to-Revenue | -2.65 | |||||
| EV-to-FCF | 1.17 | |||||
| Price-to-Net-Current-Asset-Value | 0.46 | |||||
| Price-to-Net-Cash | 1.18 | |||||
| Earnings Yield (Greenblatt) % | 64.52 |
How LAVA Therapeutics NV (LVTX) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LVTX
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 17.445 | ||
| EPS (TTM) ($) | -1.06 | ||
| Beta | 0 | ||
| Volatility % | 108.23 | ||
| 14-Day RSI | 25.82 | ||
| 14-Day ATR ($) | 0.187256 | ||
| 20-Day SMA ($) | 1.96225 | ||
| 12-1 Month Momentum % | -56.61 | ||
| 52-Week Range ($) | 1.56 - 7.38 | ||
| Shares Outstanding (Mil) | 26.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LAVA Therapeutics NV Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
LAVA Therapeutics NV Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
LAVA Therapeutics NV Frequently Asked Questions
What is LAVA Therapeutics NV(LVTX)'s stock price today?
The current price of LVTX is $1.59. The 52 week high of LVTX is $7.38 and 52 week low is $1.56.
When is next earnings date of LAVA Therapeutics NV(LVTX)?
The next earnings date of LAVA Therapeutics NV(LVTX) is 2023-05-17 Est..
Does LAVA Therapeutics NV(LVTX) pay dividends? If so, how much?
LAVA Therapeutics NV(LVTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
